6 Related NICE guidance
Details are correct at the time of consultation. Further information is available on the NICE website.
Published
-
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer. NICE technology appraisal guidance 285 (2013).
-
Ovarian cancer: The recognition and initial management of ovarian cancer. NICE clinical guideline 122 (2011).
-
Trabectedin for the treatment of relapsed ovarian cancer. NICE technology appraisal guidance 222 (2011).
-
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for the treatment of advanced ovarian cancer. NICE technology appraisal guidance 91 (2005).
-
Review of the clinical effectiveness and cost effectiveness of paclitaxel for ovarian cancer. NICE technology appraisal guidance 55 (2003).
Under development
-
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for the treatment of recurrent ovarian cancer (including review of technology appraisal no. 91 and technology appraisal no. 222). NICE technology appraisal guidance, publication expected February 2014.
-
Vintafolide in combination with pegylated liposomal doxorubicin hydrochloride for the treatment of folate receptor positive, platinum-resistant ovarian cancer. NICE technology appraisal guidance, publication expected July 2014.